296766-74-0

Basic information

• Product Name: (S)-N-(1,5-dihydroxypentan-2-yl)benzamide
• Synonyms: (S)-N-(1,5-dihydroxypentan-2-yl)benzamide
• CAS NO: 296766-74-0
• Molecular Formula: C12H17NO3
• Molecular Weight: 223.26828
• Mol File: 296766-74-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-N-(1,5-dihydroxypentan-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-(1,5-dihydroxypentan-2-yl)benzamide(296766-74-0)
• EPA Substance Registry System: (S)-N-(1,5-dihydroxypentan-2-yl)benzamide(296766-74-0)

Safety Data

• Hazardous Substances Data: 296766-74-0(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
Cilengitide is utilized as an anti-cancer agent, particularly for the treatment of aggressive malignancies such as glioblastoma and melanoma. Its mechanism of action involves the inhibition of integrins αvβ3 and αvβ5, which are crucial for the growth of new blood vessels supplying the tumor, thus starving the tumor of nutrients and oxygen and preventing its spread.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Cilengitide is used as a subject of research and development for novel cancer therapies. Its unique mode of action targeting integrins overexpressed in tumor cells makes it a valuable compound in the search for more effective and targeted treatments for cancer.
Used in Clinical Trials:
Cilengitide is employed in clinical trials to evaluate its safety, efficacy, and optimal dosages for cancer treatment. These trials are essential for determining the potential of Cilengitide as a viable cancer therapy and for identifying any side effects or interactions with other medications.
Used in Drug Combination Therapy:
Cilengitide may also be used in combination with other cancer treatments, such as chemotherapy or radiation therapy, to enhance their effectiveness. The inhibition of tumor angiogenesis by Cilengitide can make cancer cells more susceptible to the cytotoxic effects of other treatments, potentially leading to improved patient outcomes.

Upstream product

• 100-47-0 benzonitrile 
• 124126-80-3 N-benzoyl-L-glutamic acid α-methyl ester 
• 86555-46-6 dimethyl (2S)-2-benzoylaminopentanedioate 
• 6094-36-6 N-benzoyl-L-glutamic acid 

Relevant articles and documents

Directed β C-H Amination of Alcohols via Radical Relay Chaperones

A radical-mediated strategy for β C-H amination of alcohols has been developed. This approach employs a radical relay chaperone, which serves as a traceless director that facilitates selective C-H functionalization via 1,5-hydrogen atom transfer (HAT) and enables net incorporation of ammonia at the β carbon of alcohols. The chaperones presented herein enable direct access to imidate radicals, allowing their first use for H atom abstraction. A streamlined protocol enables rapid conversion of alcohols to their β-amino analogs (via in situ conversion of alcohols to imidates, directed C-H amination, and hydrolysis to NH2). Mechanistic experiments indicate HAT is rate-limiting, whereas intramolecular amination is product- and stereo-determining.

Toward the development of chemoprevention agents. Part 1: Design, synthesis, and anti-inflammatory activities of a new class of 2,5-disubstituted-dioxacycloalkanes

A new class of 2,5-disubstituted-dioxacycloalkanes were designed and synthesized via stereoselective synthetic method as cancer chemoprevention agents. The anti-inflammatory activities of these compounds were tested using the xylene-induced mouse ear edema model. Some of these compounds exhibited comparable or better anti-inflammatory activities than that of aspirin suggesting that they can be further developed as potential anti-inflammatory drug lead compounds. In addition, treatment of these anti-inflammatory agents did not prolong tail bleeding time in mice. The structure/activity relationships were also analyzed among these compounds.

5-Benzoylamino-1,3-dioxacyclanes, the method for preparing the same and their use as PKC inhibitor

The present invention discloses a series of benzoylamino-1,3-dioxacyclane compounds, of which compounds 1-21 were prepared via transacetalisation reaction between N-benzoylaminoglycol and 1,1,3,3-tetramethoxypropane; while compounds 22-48 were prepared vi

Stereoselective transacetalization of 1,1,3,3-tetramethoxypropane and N- benzoylaminodiols

The transacetalization of 1,1,3,3-tetramethoxypropane and an N- benzoylaminodiol provided stereoselectively the corresponding 2,5- disubstituted-1,3-dioxanes. The stereochemistry of the rings formed in the transacetalization depended on the structure of the amino diol, and the ratio of the products depended on the reaction conditions, as expected. This kind of stereoselective transacetalization not only gives a series of useful building blocks but also generates interesting 1,3-dioxanes which target protein kinase C.